 Ultomiris, the generalised myasthenia gravis gMG treatment developed by multinational pharmaceutical giant AstraZeneca PLC LSE:AZN, has been approved for adult treatment in Europe. The nod from the European Commission marks the first and only approval for a long-acting C5 complement inhibitor for the treatment of the debilitating autoimmune disease. 